Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Alvarez, P ^a   Carrillo, E ^a   Velez C ^a   Hita Contreras, F ^a,b   Martinez Amat A ^a,b   Rodriguez Serrano F ^a   Boulaiz, H ^a   Ortiz, R ^a,b   Melguizo, C ^a   Prados, J ^a   Aranega A ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BKT 140; CERAMIDE 1 PHOSPHATE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR7; DIPEPTIDYL PEPTIDASE IV; GRANULOCYTE COLONY STIMULATING FACTOR; MATRIX METALLOPROTEINASE 14; NATALIZUMAB; PLASMINOGEN; PLERIXAFOR; POL 6326; SPHINGOSINE 1 PHOSPHATE; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

AMINO TERMINAL SEQUENCE; BONE MARROW; CELL ADHESION; CELL HOMING; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL; HUMAN; INJECTION SITE REACTION; LIPID RAFT; NONHUMAN; PARESTHESIA; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REGULATORY MECHANISM; REVIEW; STEM CELL MOBILIZATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; ANIMAL; CELL MOTION; CLINICAL TRIAL (TOPIC); CYTOLOGY; METABOLISM; STEM CELL TRANSPLANTATION;

ANIMALS; BONE MARROW; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; STEM CELL TRANSPLANTATION;

EID: 84880178083     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/312656     Document Type: Review

References (138)

1. Gratwohl A., Baldomero H., Schmid O., Horisberger B., Bargetzi M., Urbano-Ispizua A., McDonald F., McGrath E., Notely S., Chesnel V., Gorin N. C., Ljungman P., Ruiz de Elvira C., Jouet J. P., Chir Z., Hagenbeek A., Biezen A., Sneets M., Greinix H., Lindner B., Vignetti M., Bacigalupo A., Oneto R., Bruno B., Ottinger H., Westphal M., Towlson K., Apperley J., Wilson M., Gurman G., Arat M., Arpaci F., Ertem M., Benesova K., Trnkova M., Naya M., Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplantation 2005 36 7 575 590 2-s2.0-30944454875 10.1038/sj.bmt.1705104
2. Massberg S., Von Andrian U. H., Novel trafficking routes for hematopoietic stem and progenitor cells. Annals of the New York Academy of Sciences 2009 1176 87 93 2-s2.0-70349839483 10.1111/j.1749-6632.2009.04609.x
3. Spradling A., Drummond-Barbosa D., Kai T., Stem cells find their niche. Nature 2001 414 6859 98 104 2-s2.0-0035499450 10.1038/35102160
4. Kopp H. G., Avecilla S. T., Hooper A. T., Rafii S., The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology 2005 20 5 349 356 2-s2.0-26844520899
5. Lapidot T., Dar A., Kollet O., How do stem cells find their way home? Blood 2005 106 6 1901 1910 2-s2.0-23244435467 10.1182/blood-2005-04-1417
6. Baldomero H., Gratwohl M., Gratwohl A., Tichelli A., Niederwieser D., Madrigal A., Frauendorfer K., The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplantation 2011 46 4 485 501 2-s2.0-79953700536 10.1038/bmt.2011.11
7. Gratwohl A., Baldomero H., Trends of hematopoietic stem cell transplantation in the third millennium. Current Opinion in Hematology 2009 16 6 420 426 2-s2.0-73949144252 10.1097/MOH.0b013e328330990f
8. Cohen Y., Nagler A., Umbilical cord blood transplantation-how, when and for whom? Blood Reviews 2004 18 3 167 179 2-s2.0-3042833898 10.1016/S0268- 960X(03)00064-X
9. Couban S., Simpson D. R., Barnett M. J., Bredeson C., Hubesch L., Howson-Jan K., Shore T. B., Walker I. R., Browett P., Messner H. A., Panzarella T., Lipton J. H., A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002 100 5 1525 1531 2-s2.0-0036720739 10.1182/blood-2002-01-0048
10. Ringdén O., Labopin M., Bacigalupo A., Arcese W., Schaefer U. W., Willemze R., Koc H., Bunjes D., Gluckman E., Rocha V., Schattenberg A., Frassoni F., Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. Journal of Clinical Oncology 2002 20 24 4655 4664 2-s2.0-0037115651 10.1200/JCO.2002.12.049
11. Ratajczak M. Z., Kim C. H., Abdel-Latif A., Schneider G., Kucia M., Morris A. J., Laughlin M. J., Ratajczak J., A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients. Leukemia 2012 26 1 63 72 2-s2.0-84856733415 10.1038/leu.2011.242
12. Kränkel N., Spinettib G., Amadesic S., Madedduc P., Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacology Therapeutics 2011 129 1 62 81
13. + cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells and Development 2007 16 3 347 353 2-s2.0-34347366261 10.1089/scd.2007.9995
14. + peripheral blood cells. Stem Cells and Development 2007 16 3 361 370 2-s2.0-34347325114 10.1089/scd.2007.9997
15. Haghighat A., Weiss D., Whalin M. K., Cowan D. P., Taylor W. R., Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation 2007 115 15 2049 2054 2-s2.0-34247195133 10.1161/CIRCULATIONAHA.106.665570
16. Tura O., Crawford J., Barclay G. R., Samuel K., Hadoke P. W. F., Roddie H., Davies J., Turner M. L., Granulocyte colony-stimulating factor (G-CSF) depresses angiogenesis in vivo and in vitro: implications for sourcing cells for vascular regeneration therapy. Journal of Thrombosis and Haemostasis 2010 8 7 1614 1623 2-s2.0-77955016125 10.1111/j.1538-7836.2010.03900.x
17. Chung H. K., Ko E. M., Kim S. W., Byun S. J., Chung H. J., Kwon M., Lee H. C., Yang B. C., Han D. W., Park J. K., Hong S. G., Chang W. K., Kim K. W., Antiapoptotic effects of Phe140Asn, a novel human granulocyte colony-stimulating factor mutant in H9c2 rat cardiomyocytes. Biochemistry and Molecular Biology Reports 2012 458 127 742 747
18. Fu Z. H., Dong W., Gai L. Y., Wang F., Ding R., Chen Y. D., Effect of erythropoietin combined with granulocyte-colony stimulating factor in the treatment of acute myocardial infarction in rats. Journal of Southern Medical University 2011 31 1 17 22 2-s2.0-79958278381
19. Guo Y., Liu C., He J., Effect of combined therapy of granulocyte colony stimulating factor and bone marrow mesenchymal stem cells carrying hepatocyte growth factor gene on angiogenesis of myocardial infarction in rats. Chinese Journal of Reparative and Reconstructive Surgery 2011 25 6 736 740 2-s2.0-84860639276
20. Pelus L. M., Bian H., Fukuda S., Wong D., Merzouk A., Salari H., The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Experimental Hematology 2005 33 3 295 307 2-s2.0-13844311525 10.1016/j.exphem.2004.11.008
21. Sugiyama T., Kohara H., Noda M., Nagasawa T., Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006 25 6 977 988 2-s2.0-33845445939 10.1016/j.immuni.2006.10.016
22. Méndez-Ferrer S., Lucas D., Battista M., Frenette P. S., Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008 452 7186 442 447 2-s2.0-39749164920 10.1038/nature06685
23. Balabanian K., Lagane B., Infantino S., Chow K. Y. C., Harriague J., Moepps B., Arenzana-Seisdedos F., Thelen M., Bachelerie F., The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. Journal of Biological Chemistry 2005 280 42 35760 35766 2-s2.0-27444443142 10.1074/jbc.M508234200
24. Qing M., Jones D., Springer T. A., The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999 10 4 463 471 2-s2.0-0033119201 10.1016/S1074-7613(00)80046-1
25. Rankin S. M., Chemokines and adult bone marrow stem cells. Immunology Letters 2012 145 147 254
26. Perez L. E., Alpdogan O., Shieh J.-H., Wong D., Merzouk A., Salari H., O'Reilly R. J., Van Den Brink M. R. M., Moore M. A. S., Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Experimental Hematology 2004 32 3 300 307 2-s2.0-1542327256 10.1016/j.exphem.2003.12.005
27. Flomenberg N., Devine S. M., DiPersio J. F., Liesveld J. L., McCarty J. M., Rowley S. D., Vesole D. H., Badel K., Calandra G., The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005 106 5 1867 1874 2-s2.0-23944525352 10.1182/blood-2005- 02-0468
28. Gangadhar T., Nandi S., Salgia R., The role of chemokine receptor CXCR4 in lung cancer. Cancer Biology and Therapy 2010 9 6 409 416 2-s2.0-77953720207
29. Zabel B. A., Lewén S., Berahovich R. D., Jaén J. C., Schall T. J., The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Molecular Cancer 2011 10, article no. 73 2-s2.0-79958269508 10.1186/1476-4598-10-73
30. Liles W. C., Broxmeyer H. E., Rodger E., Wood B., Hübel K., Cooper S., Hangoc G., Bridger G. J., Henson G. W., Calandra G., Dale D. C., Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003 102 8 2728 2730 2-s2.0-0141923918 10.1182/blood-2003-02-0663
31. Wang J., Shiozawa Y., Wang J., Wang Y., Jung Y., Pienta K. J., Mehra R., Loberg R., Taichman R. S., The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. Journal of Biological Chemistry 2008 283 7 4283 4294 2-s2.0-42949133032 10.1074/jbc.M707465200
32. Schutyser E., Su Y., Yu Y., Gouwy M., Zaja-Milatovic S., Van Damme J., Richmond A., Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. European Cytokine Network 2007 18 2 59 70 2-s2.0-34547889563 10.1684/ecn.2007.0087
33. Dar A., Kollet O., Lapidot T., Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Experimental Hematology 2006 34 8 967 975 2-s2.0-33746092455 10.1016/j.exphem.2006.04.002
34. Vagima Y., Lapid K., Kollet O., Goichberg P., Alon R., Lapidot T., Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis. Methods in Molecular Biology 2011 750 277 289 2-s2.0-80052637892 10.1007/978-1-61779-145-1- 19
35. Hattori K., Heissig B., Tashiro K., Honjo T., Tateno M., Shieh J.-H., Hackett N. R., Quitoriano M. S., Crystal R. G., Rafii S., Moore M. A. S., Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001 97 11 3354 3360 2-s2.0-0035383801 10.1182/blood.V97.11.3354
36. Walter D. H., Rochwalsky U., Reinhold J., Seeger F., Aicher A., Urbich C., Spyridopoulos I., Chun J., Brinkmann V., Keul P., Levkau B., Zeiher A. M., Dimmeler S., Haendeler J., Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2 275 282 2-s2.0-33846413190 10.1161/01.ATV.0000254669.12675.70
37. Kim C. H., Wu W., Wysoczynski M., Abdel-Latif A., Sunkara M., Morris A., Kucia M., Ratajczak J., Ratajczak M. Z., Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia 2012 26 1 106 116 2-s2.0-84856713252 10.1038/leu.2011.185
38. Lee H. M., Wu W., Wysoczynski M., Liu R., Zuba-Surma E. K., Kucia M., Ratajczak J., Ratajczak M. Z., Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes. Leukemia 2009 23 11 2052 2062 2-s2.0-70450284427 10.1038/leu.2009.158
39. + stem/progenitor cells to bone marrow. Blood 2004 103 8 2981 2989 2-s2.0-11144358161 10.1182/blood-2003-10-3611
40. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N. R., Crystal R. G., Besmer P., Lyden D., Moore M. A. S., Werb Z., Rafii S., Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand. Cell 2002 109 5 625 637 2-s2.0-18444389451 10.1016/S0092-8674(02)00754-7
41. Winkler I. G., Lévesque J.-P., Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Experimental Hematology 2006 34 8 996 1009 2-s2.0-33746046377 10.1016/j.exphem.2006.04.005
42. Lévesque J.-P., Hendy J., Takamatsu Y., Williams B., Winkler I. G., Simmons P. J., Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Experimental Hematology 2002 30 5 440 449 2-s2.0-0036265635 10.1016/S0301-472X(02)00788-9
43. Castellino F. J., Ploplis V. A., Structure and function of the plasminogen/plasmin system. Thrombosis and Haemostasis 2005 93 4 647 654 2-s2.0-16844384895 10.1160/TH04-12-0842
44. Gong Y., Hoover-Plow J., The plasminogen system regulating stem cell mobilization. Journal of Biomedicine and Biotechnology 2012 2012 7 437920 10.1155/2012/437920
45. Montuori N., Carriero M. V., Salzano S., Rossi G., Ragno P., The cleavage of the urokinase receptor regulates its multiple functions. Journal of Biological Chemistry 2002 277 49 46932 46939 2-s2.0-0346736507 10.1074/jbc.M207494200
46. Gazitt Y., Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occuring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia 2004 18 1 1 10 2-s2.0-0742289555 10.1038/sj.leu.2403173
47. Craddock C. F., Nakamoto B., Andrews R. G., Priestley G. V., Papayannopoulou T., Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997 90 12 4779 4788 2-s2.0-0031440743
48. Chigaev A., Winter S. S., Sklar L. A., Is prolonged stem cell mobilization detrimental for hematopoiesis? Medical Hypotheses 2011 77 6 1111 1113 2-s2.0-80755140132 10.1016/j.mehy.2011.09.015
49. Ulyanova T., Scott L. M., Priestley G. V., Jiang Y., Nakamoto B., Koni P. A., Papayannopoulou T., VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin. Blood 2005 106 1 86 94 2-s2.0-22044432420 10.1182/blood-2004-09-3417
50. Lévesque J.-P., Hendy J., Winkler I. G., Takamatsu Y., Simmons P. J., Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Experimental Hematology 2003 31 2 109 117 2-s2.0-0037317025 10.1016/S0301-472X(02)01028-7
51. Kimura Y., Ding B., Imai N., Nolan D. J., Butler J. M., Rafii S., C-kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. PLoS One 2011 6 10 2-s2.0-80055042784 10.1371/journal.pone.0026918 e26918
52. Bonig H., Priestley G. V., Oehler V., Papayannopoulou T., Hematopoietic Progenitor Cells (HPC) from Mobilized Peripheral Blood Display Enhanced Migration and Marrow Homing Compared to Steady-State Bone Marrow HPC. Experimental Hematology 2007 35 2 326 334 2-s2.0-33846374411 10.1016/j.exphem.2006.09.017
53. Wright D. E., Wagers A. J., Pathak Gulati A., Johnson F. L., Weissman I. L., Physiological migration of hematopoietic stem and progenitor cells. Science 2001 294 5548 1933 1936 2-s2.0-0035976526 10.1126/science.1064081
54. Broxmeyer H. E., Orschell C. M., Clapp D. W., Hangoc G., Cooper S., Plett P. A., Liles W. C., Li X., Graham-Evans B., Campbell T. B., Calandra G., Bridger G., Dale D. C., Srour E. F., Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. Journal of Experimental Medicine 2005 201 8 1307 1318 2-s2.0-20944440068 10.1084/jem.20041385
55. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., Mildner-Rihm C., Martin H., Zeiher A. M., Dimmeler S., Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003 102 4 1340 1346 2-s2.0-0042738942 10.1182/blood-2003-01-0223
56. Han J., Koh Y. J., Moon H. R., Ryoo H. G., Cho C.-H., Kim I., Koh G. Y., Adipose tissue is an extramedullary reservoir for functional hematopoietic stem and progenitor cells. Blood 2010 115 5 957 964 2-s2.0-77649194990 10.1182/blood-2009-05-219923
57. Pitchford S. C., Hahnel M. J., Jones C. P., Rankin S. M., Troubleshooting: quantification of mobilization of progenitor cell subsets from bone marrow in vivo. Journal of Pharmacological and Toxicological Methods 2010 61 2 113 121 2-s2.0-77950546974 10.1016/j.vascn.2010.01.013
58. Cashen A. F., Link D., Devine S., DiPersio J., Cytokines and stem cell mobilization for autologous and allogeneic transplantation. Current hematology reports 2004 3 6 406 412 2-s2.0-27644570039
59. Brown R. A., Adkins D., Goodnough L. T., Haug J. S., Todd G., Wehde M., Hendricks D., Ehlenbeck C., Laub L., DiPersio J., Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. Journal of Clinical Oncology 1997 15 9 3067 3074 2-s2.0-0030762792
60. + cell dose in blood cell transplantation for cancer therapy. Journal of Clinical Oncology 2000 18 6 1360 1377 2-s2.0-0034097402
61. Greenbaum A. M., Link D. C., Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia 2011 25 2 211 217 2-s2.0-79751532532 10.1038/leu.2010.248
62. Cencioni C., Capogrossi M. C., Napolitano M., The SDF-1/CXCR4 axis in stem cell preconditioning. Cardiovascular Research 2012 94 3 400 407
63. Duhrsen U., Villeval J. L., Boyd J., Kannourakis G., Morstyn G., Metcalf D., Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988 72 6 2074 2081 2-s2.0-0024271198
64. Lefrère F., Bernard M., Audat F., Cavazzana-Calvo M., Belanger C., Hermine O., Arnulf B., Buzyn A., Varet B., Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Leukemia and Lymphoma 1999 35 5-6 501 505 2-s2.0-0342948722
65. Fischer J. C., Frick M., Wassmuth R., Platz A., Punzel M., Wernet P., Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. British Journal of Haematology 2005 130 5 740 746 2-s2.0-27244453576 10.1111/j.1365-2141.2005. 05678.x
66. To L. B., Levesque J.-P., Herbert K. E., How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011 118 17 4530 4540 2-s2.0-80055079997 10.1182/blood-2011-06-318220
67. Motabi I. H., DiPersio J. F., Advances in stem cell mobilization. Blood Reviews 2012 26 6 267 278
68. Fruehauf S., Schmitt K., Veldwijk M. R., Topaly J., Benner A., Zeller W. J., Ho A. D., Haas R., Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. British Journal of Haematology 1999 105 3 786 794 2-s2.0-0033067494 10.1046/j.1365-2141.1999.01405.x
69. Mohty M., Ho A. D., In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Experimental Hematology 2011 39 7 723 729 2-s2.0-79960568675 10.1016/j.exphem.2011.05.004
70. Bensinger W., Appelbaum F., Rowley S., Storb R., Sanders J., Lilleby K., Gooley T., Demirer T., Schiffman K., Weaver C., Clift R., Chauncey T., Klarnet J., Montgomery P., Petersdorf S., Weiden P., Witherspoon R., Buckner C. D., Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology 1995 13 10 2547 2555 2-s2.0-0029092359
71. Gertz M. A., Wolf R. C., Micallef I. N. M., Gastineau D. A., Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplantation 2010 45 9 1396 1403 2-s2.0-77956469983 10.1038/bmt.2009.370
72. + cells. Biology of Blood and Marrow Transplantation 2013 19 4 670 675
73. Hashimoto S., Itoh M., Nishimura M., Asai T., Effect of filgrastim administration for steady-state mobilization of peripheral blood stem cells. Therapeutic Apheresis 2002 6 6 431 436 2-s2.0-0036895934 10.1046/j.1526-0968. 2002.00467.x
74. Kröger N., Renges H., Krüger W., Gutensohn K., Löliger C., Carrero I., Cortes L., Zander A. R., A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. British Journal of Haematology 2000 111 3 761 765 2-s2.0-0034490440 10.1046/j.1365-2141.2000.02412.x
75. Ings S. J., Balsa C., Leverett D., Mackinnon S., Linch D. C., Watts M. J., Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. British Journal of Haematology 2006 134 5 517 525 2-s2.0-33746513100 10.1111/j.1365-2141.2006.06223.x
76. Becker P. S., Wagle M., Matous S., Swanson R. S., Pihan G., Lowry P. A., Stewart F. M., Heard S. O., Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biology of Blood and Marrow Transplantation 1997 3 1 45 49 2-s2.0-0031113562
77. Dincer A. P., Gottschall J., Margolis D. A., Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. Journal of Pediatric Hematology/Oncology 2004 26 11 761 763 2-s2.0-9644265310 10.1097/00043426-200411000-00015
78. Ratajczak M. Z., Lee H., Wysoczynski M., Wan W., Marlicz W., Laughlin M. J., Kucia M., Janowska-Wieczorek A., Ratajczak J., Novel insight into stem cell mobilization-Plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia 2010 24 5 976 985 2-s2.0-77952422757 10.1038/leu.2010.53
79. Sheridan W. P., Begley C. G., Juttner C. A., Szer J., Bik To L., Maher D., McGrath K. M., Morstyn G., Fox R. M., Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992 339 8794 640 644 2-s2.0-0026504705 10.1016/0140-6736(92)90795-5
80. Schwartzberg L. S., Birch R., Hazelton B., Tauer K. W., Lee P. Jr., Altemose R., George C., Blanco R., Wittlin F., Cohen J., Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. Journal of hematotherapy 1992 1 4 317 327 2-s2.0-0027019408
81. Dazzi C., Cariello A., Rosti G., Argnani M., Sebastiani L., Ferrari E., Zornetta L., Monti G., Nicoletti P., Baioni M., Salvucci M., Scarpi E., Marangolo M., Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma? Leukemia and Lymphoma 2000 39 3-4 301 310 2-s2.0-0034485697
82. Dingli D., Nowakowski G. S., Dispenzieri A., Lacy M. Q., Hayman S., Litzow M. R., Gastineau D. A., Gertz M. A., Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clinical Lymphoma and Myeloma 2006 6 5 384 388 2-s2.0-33646594131 10.3816/CLM.2006.n.014
83. Kim S., Kim H.-J., Park J. S., Lee J., Chi H.-S., Park C. J., Huh J., Suh C., Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Annals of Hematology 2005 84 11 742 747 2-s2.0-26844502883 10.1007/s00277-005-1103-8
84. Hosing C., Saliba R. M., Ahlawat S., Körbling M., Kebriaei P., Alousi A., De Lima M., Okoroji J.-G., McMannis J., Qazilbash M., Anderlini P., Giralt S., Champlin R. E., Khouri I., Popat U., Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. American Journal of Hematology 2009 84 6 335 337 2-s2.0-66849102131 10.1002/ajh.21400
85. Kuittinen T., Nousiainen T., Halonen P., Mahlamäki E., Jantunen E., Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation 2004 33 9 907 912 2-s2.0-2442699073 10.1038/sj.bmt. 1704466
86. Wuchter P., Ran D., Bruckner T., Schmitt T., Witzens-Harig M., Neben K., Goldschmidt H., Ho A. D., Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biology of Blood and Marrow Transplantation 2010 16 4 490 499 2-s2.0-77649335991 10.1016/j.bbmt.2009.11.012
87. Olivieri A., Marchetti M., Lemoli R., Tarella C., Iacone A., Lanza F., Rambaldi A., Bosi A., Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplantation 2012 47 3 342 351 2-s2.0-84858076675 10.1038/bmt.2011.82
88. Petit I., Szyper-Kravitz M., Nagler A., Lahav M., Peled A., Habler L., Ponomaryov T., Taichman R. S., Arenzana-Seisdedos F., Fujii N., Sandbank J., Zipori D., Lapidot T., G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology 2002 3 7 687 694 2-s2.0-0036302147 10.1038/ni813
89. Bensinger W., DiPersio J. F., McCarty J. M., Improving stem cell mobilization strategies: future directions. Bone Marrow Transplantation 2009 43 3 181 195 2-s2.0-60349086555 10.1038/bmt.2008.410
90. Demirer T., Buckner C. D., Gooley T., Appelbaum F. R., Rowley S., Chauncey T., Lilleby K., Storb R., Bensinger W. I., Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplantation 1996 17 6 937 941 2-s2.0-0030037744
91. Pusic I., Jiang S. Y., Landua S., Uy G. L., Rettig M. P., Cashen A. F., Westervelt P., Vij R., Abboud C. N., Stockerl-Goldstein K. E., Sempek D. S., Smith A. L., DiPersio J. F., Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. Biology of Blood and Marrow Transplantation 2008 14 9 1045 1056 2-s2.0-49449091143 10.1016/j.bbmt.2008.07.004
92. Jantunen E., Itälä M., Siitonen T., Kuittinen T., Heiskanen J., Koivunen E., Juvonen E., Silvennoinen R., Nousiainen T., Koistinen P., Volin L., Remes K., Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. Bone Marrow Transplantation 2008 41 3 239 244 2-s2.0-39349098418 10.1038/sj.bmt.1705897
93. Haas R., Möhle R., Frühauf S., Goldschmidt H., Witt B., Flentje M., Wannenmacher M., Hunstein W., Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994 83 12 3787 3794 2-s2.0-0028282857
94. Lysak D., Koza V., Steinerova K., Jindra P., Vozobulova V., Schutzova M., Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Annals of Hematology 2005 84 7 456 461 2-s2.0-20944432005 10.1007/s00277-005-1008-6
95. Laszlo D., Galieni P., Raspadori D., Tozzi M., Lauria F., Martinelli G., Fludarabine combination regimen severely affected peripheral blood stem cell mobilization. Acta Haematologica 2004 111 4 228 229 2-s2.0-2642539880 10.1159/000077572
96. Popat U., Saliba R., Thandi R., Hosing C., Qazilbash M., Anderlini P., Shpall E., McMannis J., Körbling M., Alousi A., Andersson B., Nieto Y., Kebriaei P., Khouri I., de Lima M., Weber D., Thomas S., Wang M., Jones R., Champlin R., Giralt S., Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biology of Blood and Marrow Transplantation 2009 15 6 718 723 2-s2.0-67349243088 10.1016/j.bbmt.2009.02.011
97. Sevilla J., Guillén M., Castillo A., Prudencio M., González-Vicent M., Lassaletta Á., Cormenzana M., Ramírez M., Pérez-Martínez A., Madero L., Di'az-Pérez M. Á., Defining "poor mobilizer" in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. Cytotherapy 2013 15 1 132 137
98. Han X., Ma L., Zhao L., He X., Liu P., Zhou S., Yang J., Qin Y., Yang S., Yao J., Shi Y., Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study. Journal of Clinical Apheresis 2012 27 2 64 74 2-s2.0-84859704128 10.1002/jca.21204
99. + cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplantation 2006 38 3 189 196 2-s2.0-33746308673 10.1038/sj.bmt.1705431
100. Suzuya H., Watanabe T., Nakagawa R., Watanabe H., Okamoto Y., Onishi T., Abe T., Kawano Y., Kagami S., Takaue Y., Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sanguinis 2005 89 4 229 235 2-s2.0-27844555304 10.1111/j.1423-0410. 2005.00701.x
101. Zubair A. C., Grant R., Wu W., Tun H., Rivera C., Moreno-Aspitia A., Joyce M., Roy V., Colon-Otero G., Solberg L. A., Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion 2008 48 6 1106 1114 2-s2.0-44849134815 10.1111/j.1537-2995.2008.01651.x
102. Molineux G., Pojda Z., Hampson I. N., Lord B. I., Dexter T. M., Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 1990 76 10 2153 2158 2-s2.0-0025258439
103. Gordan L. N., Sugrue M. W., Lynch J. W., Williams K. D., Khan S. A., Wingard J. R., Moreb J. S., Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma 2003 44 5 815 820 2-s2.0-0037403201 10.1080/1042819031000067585
104. Ferraro F., Lymperi S., Méndez-Ferrer S., Saez B., Spencer J. A., Yeap B. Y., Masselli E., Graiani G., Prezioso L., Rizzini E. L., Mangoni M., Rizzoli V., Sykes S. M., Lin C. P., Frenette P. S., Quaini F., Scadden D. T., Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Science translational medicine 2011 3 104, article 104ra101 2-s2.0-84857379998
105. Lysák D., Hrabětová M., Vrzalová J., Koza V., Navrátilová J., Svoboda T., Jungová A., Topolčan O., Changes of cytokine levels during granulocyte-colony-stimulating factor stem cell mobilization in healthy donors: association with mobilization efficiency and potential predictive significance. Transfusion 2011 51 2 319 327 2-s2.0-79951631821 10.1111/j.1537-2995.2010.02863.x
106. Cashen A. F., Nervi B., DiPersio J., AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncology 2007 3 1 19 27 2-s2.0-33847040391 10.2217/14796694.3.1.19
107. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. Journal of Clinical Oncology 2004 22 6 1095 1102 2-s2.0-1842509856 10.1200/JCO.2004.07.131
108. Duarte R. F., Shaw B. E., Marín P., Kottaridis P., Ortiz M., Morante C., Delgado J., Gayoso J., Goterriz R., Martínez-Chamorro C., Mateos-Mazón J. J., Ramírez C., De La Rubia J., Achtereekte H., Gandhi P. J., Douglas K. W., Russell N. H., Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplantation 2011 46 1 52 58 2-s2.0-78651347616 10.1038/bmt.2010.54
109. + hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005 45 3 295 300 2-s2.0-20144362394 10.1111/j.1537-2995.2005.04222.x
110. Douglas K. W., Parker A. N., Hayden P. J., Rahemtulla A., D'Addio A., Lemoli R. M., Rao K., Maris M., Pagliuca A., Uberti J., Scheid C., Noppeney R., Cook G., Bokhari S. W., Worel N., Mikala G., Masszi T., Taylor R., Treisman J., Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplantation 2012 47 1 18 23 2-s2.0-84855749342 10.1038/bmt.2011.9
111. Abhyankar S., Dejarnette S., Aljitawi O., Ganguly S., Merkel D., McGuirk J., A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplantation 2012 47 4 483 487 2-s2.0-84859467357 10.1038/bmt.2011.133
112. Kessans M. R., Gatesman M. L., Kockler D. R., Plerixafor: a peripheral blood stem cell mobilizer. Pharmacotherapy 2010 30 5 485 492 2-s2.0-77951701928 10.1592/phco.30.5.485
113. Jantunen E., Novel strategies for blood stem cell mobilization: special focus on plerixafor. Expert Opinion on Biological Therapy 2011 11 9 1241 1248 2-s2.0-80051542003 10.1517/14712598.2011.601737
114. Cashen A., Lopez S., Gao F., Calandra G., MacFarland R., Badel K., DiPersio J., A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 2008 14 11 1253 1261 2-s2.0-53749085874 10.1016/j.bbmt.2008.08.011
115. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplantation 2008 41 4 331 338 2-s2.0-40249093217 10.1038/sj.bmt.1705908
116. Micallef I. N., Stiff P. J., DiPersio J. F., Maziarz R. T., McCarty J. M., Bridger G., Calandra G., Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin Lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biology of Blood and Marrow Transplantation 2009 15 12 1578 1586 2-s2.0-70350566151 10.1016/j.bbmt.2009.08.005
117. Steinberg M., Silva M., Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-hodgkin's lymphoma or multiple myeloma. Clinical Therapeutics 2010 32 5 821 843 2-s2.0-77954804850 10.1016/j.clinthera.2010.05. 007
118. Stiff P., Micallef I., McCarthy P., Magalhaes-Silverman M., Weisdorf D., Territo M., Badel K., Calandra G., Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biology of Blood and Marrow Transplantation 2009 15 2 249 256 2-s2.0-58249125135 10.1016/j.bbmt.2008.11.028
119. Jantunen E., Kvalheim G., Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. European Journal of Haematology 2010 85 6 463 471 2-s2.0-78349254580 10.1111/j.1600-0609.2010.01520.x
120. Dugan M. J., Maziarz R. T., Bensinger W. I., Nademanee A., Liesveld J., Badel K., Dehner C., Gibney C., Bridger G., Calandra G., Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplantation 2010 45 1 39 47 2-s2.0-75149188308 10.1038/bmt.2009.119
121. Yannaki E., Papayannopoulou T., Jonlin E., Zervou F., Karponi G., Xagorari A., Becker P., Psatha N., Batsis I., Kaloyannidis P., Tahynopoulou V., Constantinou V., Bouinta A., Kotta K., Athanassiadou A., Anagnostopoulos A., Fassas A., Stamatoyannopoulos G., Hematopoietic stem cell mobilization for gene therapy of adult patients with severe Β -thalassemia results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Molecular Therapy 2012 20 1 230 238 2-s2.0-84856962945 10.1038/mt.2011.195
122. Saure C., Weigelt C., Schroeder T., Klärner V., Galonska L., Haas R., Kobbe G., Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer. Acta Haematologica 2010 124 4 235 238 2-s2.0-78449257160 10.1159/000321509
123. Sinha S., Gastineau D., Micallef I., Hogan W., Ansell S., Buadi F., Dingli D., Dispenzieri A., Gertz M., Greiner C., Hayman S., Inwards D., Johnston P., Lacy M., Litzow M., Porrata L., Winters J. L., Kumar S., Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplantation 2011 46 7 943 949 2-s2.0-79960200361 10.1038/bmt.2010.236
124. Awan F. T., Kochuparambil S. T., Deremer D., Cumpston A., Craig M., Jillella A., Hamadani M., Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and Filgrastim-based peripheral blood progenitor cell mobilization. Journal of Oncology 2012 2012 5 931071 10.1155/2012/931071
125. Zohren F., Toutzaris D., Klärner V., Hartung H.-P., Kieseier B., Haas R., The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34 hematopoietic progenitor cells in humans. Blood 2008 111 7 3893 3895 2-s2.0-43549090004 10.1182/blood-2007-10-120329
126. Bonig H., Wundes A., Chang K.-H., Lucas S., Papayannopoulou T., Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008 111 7 3439 3441 2-s2.0-43549101765 10.1182/blood-2007-09-112052
127. Schmitt S., Weinhold N., Dembowsky K., First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HCS) in multiple myeloma (MM). Blood 116 abstract 824 21. Proceedings of the ASH Annual Meeting Abstracts, 2010
128. Nagler A., Shimoni A., Avivi I., Rowe J. M., Beider K., Hardan I., Abraham M., Wald H., Galun E., Shaw H. L., Eizenberg O., Peled A., BKT140 is a novel CXCR4 antagonist with stem cell mobilization and antimyeloma effects: an open-label first human trial in patients with multiple myeloma undergoing stem cell mobilization for autologous transplantation. Blood 116 abstract 2260 21. Proceedings of the ASH Annual Meeting Abstracts, 2010
129. Ghadge S. K., Mühlstedt S., Özcelik C., Bader M., SDF-1 α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacology and Therapeutics 2011 129 1 97 108 2-s2.0-78650514210 10.1016/j.pharmthera. 2010.09.011
130. Wang Y., Luther K., Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1 α /CXCR4 signaling pathway. Progress in Molecular Biology and Translational Science 2012 111 265 284
131. Wen Z., Zheng S., Zhou C., Wang J., Wang T., Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. Journal of Cellular and Molecular Medicine 2011 15 5 1032 1043 2-s2.0-79957582277 10.1111/j.1582-4934. 2010.01255.x
132. Karapetyan A. V., Klyachkin Y. M., Selim S., Sunkara M., Ziada K. M., Cohen D. A., Zuba-Surma E. K., Ratajczak J., Smyth S. S., Ratajczak M. Z., Morris A. J., Abdel-Latif A., Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow derived stem cell in patients with acute myocardial infarction. Stem Cells and Development 2013 22 11 1645 1656 10.1089/scd.2012.0488
133. Wen Z., Zheng S., Zhou C., Yuan W., Wang J., Wang T., Bone marrow mesenchymal stem cells for post-myocardial infarction cardiac repair: microRNAs as novel regulators. Journal of Cellular and Molecular Medicine 2012 16 4 657 671
134. Hong S. J., Choi S. C., Kim J. S., Shim W. J., Park S. M., Ahn C. M., Park J. H., Kim Y. H., Lim D.-S., Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-Month effects on coronary flow reserve and angiogenic cell mobilisation. Heart 2010 96 10 756 764 2-s2.0-77952666058 10.1136/hrt.2009.182683
135. Harada M., Qin Y., Takano H., Minamino T., Zou Y., Toko H., Ohtsuka M., Matsuura K., Sano M., Nishi J.-I., Iwanaga K., Akazawa H., Kunieda T., Zhu W., Hasegawa H., Kunisada K., Nagai T., Nakaya H., Yamauchi-Takihara K., Komuro I., G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nature Medicine 2005 11 3 305 311 2-s2.0-20144388775 10.1038/nm1199
136. Zohlnhöfer D., Ott I., Mehilli J., Schömig K., Michalk F., Ibrahim T., Meisetschläger G., Von Wedel J., Bollwein H., Seyfarth M., Dirschinger J., Schmitt C., Schwaiger M., Kastrati A., Schömig A., Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. Journal of the American Medical Association 2006 295 9 1003 1010 2-s2.0-33644588885 10.1001/jama.295.9.1003
137. Campbell T. B., Sevin A., Coombs R. W., Peterson G. C., Rosandich M., Kuritzkes D. R., Mladenovic J., Landay A., Wong R., Ambruso D., Miles S., Pomerantz R. J., Schooley R. T., Changes in human immunodeficiency virus type 1 virus lead during mobilization and harvesting of hemopoietic progenitor cells. Blood 2000 95 1 48 55 2-s2.0-0033985449
138. + stem cells in advanced human immunodeficiency virus type 1 disease. Journal of Infectious Diseases 2000 181 1 148 157 2-s2.0-0033972199 10.1086/315168